pipette
ENEnglish

Tumor-responsive AAV arms cancer cells to enhance CAR-T cell therapy in solid tumors

Z. Kong, Y. Wang, Y. Zhao, A. Yan, X. Wen, X. Xie, L. Wang, Z. Fan, Y. Shu, J. Wang

PreprintAfirmaciones fuertes, leer con cuidadoUso en el mundo real

En palabras de los autores

Chimeric antigen receptor (CAR)-T-cell therapy remains limited in solid tumors by the scarcity of suitable target antigens and an immunosuppressive tumor microenvironment. Here, we developed a tumor-responsive recombinant adeno-associated virus (rAAV) strategy that harnesses aberrant NF-{kappa}B activity to establish a shared synthetic CAR target across tumor types. Using an NF-{kappa}B-responsive decoy minimal promoter (DMP), rAAV-SA drove tumor-preferential surface expression of a synthetic antigen (SA), enabling antigen-dependent CAR-T-cell activation, degranulation, and cytotoxicity. Systemic rAAV-SA delivery combined with CAR-T cells produced antitumor activity in triple-negative breast cancer (TNBC) and colorectal cancer xenograft models. We subsequently engineered rAAV-ARMS (antigen redirection and multifunctional secreted effectors), integrating SA expression with tumor-local production of an IL-15/IL-15R sushi-domain fusion, CXCL10, and IFN-{gamma}. Compared with antigen redirection alone, rAAV-ARMS enhanced CAR-T-cell-mediated killing in three-dimensional tumor spheroids and, in a TNBC xenograft model, increased intratumoral T-cell accumulation and improved the efficacy of intravenously administered CAR-T cells, without overt systemic toxicity under the conditions examined. These findings establish a tumor-programmed platform for target-redirected universal CAR-T-cell therapy in solid tumors.

Resultado principalLimitación que admiten los autores

Apareció: miércoles, 18 de noviembre. bioRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.11.16.766910